Teva Pharmaceuticals
TEVA
About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Employees: 35,686
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
89% more call options, than puts
Call options by funds: $589M | Put options by funds: $312M
24% more repeat investments, than reductions
Existing positions increased: 200 | Existing positions reduced: 161
9% more capital invested
Capital invested by funds: $10.9B [Q1] → $11.9B (+$1.01B) [Q2]
0.73% more ownership
Funds ownership: 62.09% [Q1] → 62.82% (+0.73%) [Q2]
4% less funds holding
Funds holding: 552 [Q1] → 532 (-20) [Q2]
12% less funds holding in top 10
Funds holding in top 10: 26 [Q1] → 23 (-3) [Q2]
18% less first-time investments, than exits
New positions opened: 55 | Existing positions closed: 67
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
UBS
Ashwani Verma
|
$23
|
Buy
Maintained
|
26 Jun 2025 |
Financial journalist opinion
Based on 11 articles about TEVA published over the past 30 days
